ABSTRACT

Purpose: Determine the risk of immunomodulatory therapy (IMT) for COVID-19 infection morbidity.

Method: A telemedicine survey on patients of a referral uveitis clinic was performed. Signs of infection, habits, and hospitalizations during the 7 months of the COVID-19 pandemic prior to the study date were recorded. Suggestive findings in chest CT scan and/or positive RT-PCR were considered as confirmed COVID-19 infection while those with only suggestive symptoms were considered as suspected cases. Risk factors including sanitary measures and IMT were compared between patients with confirmed cases and patients without infection.

Result: 694 patients were included. Eight patients were identified as confirmed cases and 22 patients as suspected cases of COVID-19 infection. Close contact with infected persons was the only significant risk factor for contracting COVID-19.

Conclusion: Using IMT did not affect hospitalization and/or ICU admission and can thus be continued during the pandemic, provided that instructions for preventive measures are followed.

摘要

目的：确定免疫调节疗法 (IMT) 对 COVID-19 感染发病率的风险。

方法：对转诊葡萄膜炎诊所的患者进行远程医疗调查。记录了研究日期前 COVID-19 大流行 7 个月内的感染迹象、习惯和住院情况。胸部 CT 扫描的提示性发现和/或 RT-PCR 阳性被认为是确诊的 COVID-19 感染，而那些只有提示性症状的被认为是疑似病例。比较确诊病例和未感染患者的卫生措施和IMT等危险因素。

结果：共纳入694名患者。8 名患者被确定为确诊病例，22 名患者为 COVID-19 感染疑似病例。与感染者密切接触是感染 COVID-19 的唯一重要风险因素。

结论：使用 IMT 不会影响住院和/或入住 ICU，因此可以在大流行期间继续使用，前提是遵循预防措施的说明。